Clinimetrics and feasibility of the Italian version of the Frontal Assessment Battery (FAB) in non-demented Parkinson's disease patients.


Journal

Journal of neural transmission (Vienna, Austria : 1996)
ISSN: 1435-1463
Titre abrégé: J Neural Transm (Vienna)
Pays: Austria
ID NLM: 9702341

Informations de publication

Date de publication:
05 2023
Historique:
received: 20 02 2023
accepted: 18 03 2023
medline: 25 4 2023
pubmed: 29 3 2023
entrez: 28 3 2023
Statut: ppublish

Résumé

This study aimed at assessing the cross-sectional and longitudinal clinimetrics and feasibility of the Frontal Assessment Battery (FAB) in non-demented Parkinson's disease (PD) patients. N = 109 PD patients underwent the FAB and the Montreal Cognitive Assessment (MoCA). A subsample of patients further underwent a thorough motor, functional and behavioral evaluation (the last including measures of anxiety, depression and apathy). A further subsample was administered a second-level cognitive battery tapping on attention, executive functioning, language, memory, praxis and visuo-spatial abilities. The following properties of the FAB were tested: (1) concurrent validity and diagnostics against the MoCA; (2) convergent validity against the second-level cognitive battery; (4) association with motor, functional and behavioral measures; (5) capability to discriminate patients from healthy controls (HCs; N = 96); (6) assessing its test-retest reliability, susceptibility to practice effects and predictive validity against the MoCA, as well as deriving reliable change indices (RCIs) for it, at a ≈ 6-month interval, within a subsample of patients (N = 33). The FAB predicted MoCA scores at both T0 and T1, converged with the vast majority of second-level cognitive measures and was associated with functional independence and apathy. It accurately identified cognitive impairment (i.e., a below-cut-off MoCA score) in patients, also discriminating patients from HCs. The FAB was reliable at retest and free of practice effects; RCIs were derived according to a standardized regression-based approach. The FAB is a clinimetrically sound and feasible screener for detecting dysexecutive-based cognitive impairment in non-demented PD patients.

Sections du résumé

BACKGROUND
This study aimed at assessing the cross-sectional and longitudinal clinimetrics and feasibility of the Frontal Assessment Battery (FAB) in non-demented Parkinson's disease (PD) patients.
METHODS
N = 109 PD patients underwent the FAB and the Montreal Cognitive Assessment (MoCA). A subsample of patients further underwent a thorough motor, functional and behavioral evaluation (the last including measures of anxiety, depression and apathy). A further subsample was administered a second-level cognitive battery tapping on attention, executive functioning, language, memory, praxis and visuo-spatial abilities. The following properties of the FAB were tested: (1) concurrent validity and diagnostics against the MoCA; (2) convergent validity against the second-level cognitive battery; (4) association with motor, functional and behavioral measures; (5) capability to discriminate patients from healthy controls (HCs; N = 96); (6) assessing its test-retest reliability, susceptibility to practice effects and predictive validity against the MoCA, as well as deriving reliable change indices (RCIs) for it, at a ≈ 6-month interval, within a subsample of patients (N = 33).
RESULTS
The FAB predicted MoCA scores at both T0 and T1, converged with the vast majority of second-level cognitive measures and was associated with functional independence and apathy. It accurately identified cognitive impairment (i.e., a below-cut-off MoCA score) in patients, also discriminating patients from HCs. The FAB was reliable at retest and free of practice effects; RCIs were derived according to a standardized regression-based approach.
DISCUSSION
The FAB is a clinimetrically sound and feasible screener for detecting dysexecutive-based cognitive impairment in non-demented PD patients.

Identifiants

pubmed: 36976351
doi: 10.1007/s00702-023-02624-7
pii: 10.1007/s00702-023-02624-7
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

687-696

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Références

Aiello EN, Rimoldi S, Bolognini N, Appollonio I, Arcara G (2022a) Psychometrics and diagnostics of Italian cognitive screening tests: a systematic review. Neurol Sci 43:821–845
pubmed: 34816316 doi: 10.1007/s10072-021-05683-4
Aiello EN, Gramegna C, Esposito A, Gazzaniga V, Zago S, Difonzo T, Bolognini N (2022b) The montreal cognitive assessment (MoCA): updated norms and psychometric insights into adaptive testing from healthy individuals in Northern Italy. Aging Clin Exp Res 34: 375–382.
Aiello EN, Esposito A, Appollonio I, Bolognini N (2022c) Diagnostic properties of the Frontal Assessment Battery (FAB) in Italian healthy adults. Aging Clin Exp Res 34:1021–1026
pubmed: 34981429 doi: 10.1007/s40520-021-02035-2
Amboni M, Cozzolino A, Longo K, Picillo M, Barone P (2008) Freezing of gait and executive functions in patients with Parkinson’s disease. Mov Disord 23:395–400
pubmed: 18067193 doi: 10.1002/mds.21850
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (5th ed.)
Appollonio I, Leone M, Isella V, Piamarta F, Consoli T, Villa ML, Nichelli P (2005) The frontal assessment battery (FAB): normative values in an Italian population sample. Neurol Sci 26:108–116
pubmed: 15995827 doi: 10.1007/s10072-005-0443-4
Barbarotto R, Laiacona M, Frosio R, Vecchio M, Farinato A, Capitani E (1998) A normative study on visual reaction times and two Stroop colour-word tests. Italian J Neurol Sci 19:161–170
doi: 10.1007/BF00831566
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571
pubmed: 13688369 doi: 10.1001/archpsyc.1961.01710120031004
Benton AL, Varney NR, Hamsher KD (1978) Visuospatial judgment: a clinical test. Arch Neurol 35:364–367
pubmed: 655909 doi: 10.1001/archneur.1978.00500300038006
Biundo R, Weis L, Facchini S, Formento-Dojot P, Vallelunga A, Pilleri M, Antonini A (2014) Cognitive profiling of Parkinson disease patients with mild cognitive impairment and dementia. Parkinsonism Relat Disord 20:394–399
pubmed: 24495708 doi: 10.1016/j.parkreldis.2014.01.009
Biundo R, Weis L, Pilleri M, Facchini S, Formento-Dojot P, Vallelunga A, Antonini A (2013) Diagnostic and screening power of neuropsychological testing in detecting mild cognitive impairment in Parkinson’s disease. J Neural Transm 120:627–633
pubmed: 23483334 doi: 10.1007/s00702-013-1004-2
Cahn DA, Sullivan EV, Shear PK, Pfefferbaum A, Heit G, Silverberg G (1998) Differential contributions of cognitive and motor component processes to physical and instrumental activities of daily living in Parkinson’s disease. Arch Clin Neuropsychol 13:575–583
pubmed: 14590618
Caltagirone C, Gainotti G, Masullo C, Miceli G (1979) Validity of some neuropsychological tests in the assessment of mental deterioration. Acta Psychiatr Scand 60:50–56
pubmed: 474177 doi: 10.1111/j.1600-0447.1979.tb00264.x
Capasso R, Miceli G (2001) Esame Neuropsicologico per l'Afasia: ENPA . Springer Science & Business Media
Carlesimo GA, Caltagirone C, Gainotti G (1996) The mental deterioration battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. Eur Neurol 36:378–384
pubmed: 8954307 doi: 10.1159/000117297
Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D (2010) A recommended scale for cognitive screening in clinical trials of Parkinson’s disease. Movem Disord 25:2501–2507
doi: 10.1002/mds.23362
Chung SJ, Yoo HS, Lee HS, Lee YH, Baik K, Jung JH, Lee PH (2021) Baseline cognitive profile is closely associated with long-term motor prognosis in newly diagnosed Parkinson’s disease. J Neurol 268:4203–4212
pubmed: 33942161 doi: 10.1007/s00415-021-10529-2
Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: a frontal assessment battery at bedside. Neurology 55:1621–1626
pubmed: 11113214 doi: 10.1212/WNL.55.11.1621
Duff K (2012) Evidence-based indicators of neuropsychological change in the individual patient: relevant concepts and methods. Arch Clin Neuropsychol 27:248–261
pubmed: 22382384 pmcid: 3499091 doi: 10.1093/arclin/acr120
D’Iorio A, Maggi G, Vitale C, Trojano L, Santangelo G (2018) “Pure apathy” and cognitive dysfunctions in Parkinson’s disease: a meta-analytic study. Neurosci Biobehav Rev 94:1–10
pubmed: 30114389 doi: 10.1016/j.neubiorev.2018.08.004
Fahn S, Elton RL, UPDRS program members (1987) Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB (Eds) Recent developments in Parkinson’s disease, pp. 153–163
Federico A, Trentin M, Zanette G, Mapelli D, Picelli A, Smania N, Tamburin S (2017) Diagnosing mild cognitive impairment in Parkinson’s disease: which tests perform best in the Italian population? Neurol Sci 38:1461–1468
pubmed: 28550344 doi: 10.1007/s10072-017-3000-z
Gasca‐Salas, C., Duff‐Canning, S., Armstrong, M. J., Eslinger, P. J., Schneider, R. B., Kennedy, N., ... & Marras, C. (2020). Parkinson disease with mild cognitive impairment: Domain‐specific cognitive complaints predict dementia. Acta Neurologica Scandinavica, 142, 585–596.
Giovagnoli AR, Del Pesce M, Mascheroni S, Simoncelli M, Laiacona M, Capitani E (1996) Trail making test: normative values from 287 normal adult controls. Neurol Sci 17:305–309
Hurtado-Pomares M, Carmen Terol-Cantero M, Sánchez-Pérez A, Peral-Gómez P, Valera-Gran D, Navarrete-Muñoz EM (2018) The frontal assessment battery in clinical practice: a systematic review. Int J Geriatr Psychiatry 33:237–251
pubmed: 28627719 doi: 10.1002/gps.4751
Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Parkinson Study Group (1990) Variable expression of Parkinson’s disease: a base-line analysis of the DAT ATOP cohort. Neurology 40:1529–1529
pubmed: 2215943 doi: 10.1212/WNL.40.10.1529
Kataoka H, Tanaka N, Saeki K, Kiriyama T, Ueno S (2014) Low frontal assessment battery score as a risk factor for falling in patients with Hoehn-Yahr Stage III Parkinson’s disease: a 2-year prospective study. Eur Neurol 71:187–192
pubmed: 24457474 doi: 10.1159/000355532
Kim HY (2013) Statistical notes for clinical researchers: assessing normal distribution (2) using skewness and kurtosis. Restor Dent Endod 38:52–54
pubmed: 23495371 pmcid: 3591587 doi: 10.5395/rde.2013.38.1.52
Kudlicka A, Clare L, Hindle JV (2011) Executive functions in Parkinson’s disease: systematic review and meta-analysis. Mov Disord 26:2305–2315
pubmed: 21971697 doi: 10.1002/mds.23868
Kulisevsky J, Pagonabarraga J (2009) Cognitive impairment in Parkinson’s disease: tools for diagnosis and assessment. Mov Disord 24:1103–1110
pubmed: 19353727 doi: 10.1002/mds.22506
Larner AJ (2019) New unitary metrics for dementia test accuracy studies. Prog Neurol Psychiatry 23:21–25
doi: 10.1002/pnp.543
Larner AJ (2021b). Paired measures. In: Larner AJ (ed) The 2x2 Matrix. Contingency, Confusion, and the Metrics of Binary Classification, pp. 15–48
Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Emre M (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement disorder society task force guidelines. Movem Disord 27:349–356
doi: 10.1002/mds.24893
Litvan I, Kieburtz K, Tröster AI, Aarsland D (2018) Strengths and challenges in conducting clinical trials in Parkinson’s disease mild cognitive impairment. Mov Disord 33:520–527
pubmed: 29573469 doi: 10.1002/mds.27345
Marconi R, Antonini A, Barone P, Colosimo C, Avarello TP, Bottacchi E, Morgante L (2012) Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. Neurol Sci 33:585–593
pubmed: 22048791 doi: 10.1007/s10072-011-0807-x
Monaco M, Costa A, Caltagirone C, Carlesimo GA (2013) Forward and backward span for verbal and visuo-spatial data: standardization and normative data from an Italian adult population. Neurol Sci 34:749–754
pubmed: 22689311 doi: 10.1007/s10072-012-1130-x
Novelli G, Papagno C, Capitani E, Laiacona M, Cappa SF, Vallar G (1986) Tre test clinici di ricerca e produzione lessicale. Taratura su sogetti normali. Arch Psicol Neurol Psichiatr 47:278–296
Paulwoods S, Tröster AI (2003) Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson’s disease. J Int Neuropsychol Soc 9:17–24
doi: 10.1017/S1355617703910022
Petkus AJ, Filoteo JV, Schiehser DM, Gomez ME, Hui JS, Jarrahi B, Petzinger GM (2020) Mild cognitive impairment, psychiatric symptoms, and executive functioning in patients with Parkinson’s disease. Int J Geriat Psychiatry 35:396–404
doi: 10.1002/gps.5255
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Deuschl, G (2015) MDS clinical diagnostic criteria for Parkinson's disease. Movem Disord 30: 1591–1601.
Puente AN, Cohen ML, Aita S, Brandt J (2016) Behavioral ratings of executive functioning explain instrumental activities of daily living beyond test scores in Parkinson’s disease. Clin Neuropsychol 30:95–106
pubmed: 26789092 doi: 10.1080/13854046.2015.1133847
Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, Obeso JA (2009) Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms. Lancet Neurol 8:1128–1139
pubmed: 19909911 doi: 10.1016/S1474-4422(09)70293-5
Santangelo G, Raimo S, Siciliano M, D’Iorio A, Piscopo F, Cuoco S, Trojano L (2017) Assessment of apathy independent of physical disability: validation of the Dimensional Apathy Scale in Italian healthy sample. Neurol Sci 38:303–309
pubmed: 27844173 doi: 10.1007/s10072-016-2766-8
Schwab RS, England AC (1969) Projection technique for evaluating surgery in Parkinson’s disease. In: Gillingham FJ, Donaldson MC (eds) Third Symposium on Parkinson’s Disease, pp. 152–157
Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, Violante MR (2018) Global scales for cognitive screening in Parkinson’s disease: critique and recommendations. Movem Disord 33:208–218
doi: 10.1002/mds.27233
Smulders K, van Nimwegen M, Munneke M, Bloem BR, Kessels RP, Esselink RA (2013) Involvement of specific executive functions in mobility in Parkinson’s disease. Parkinsonism Relat Disord 19:126–128
pubmed: 22771282 doi: 10.1016/j.parkreldis.2012.06.010
Solca F, Aiello EN, Migliore S, Torre S, Carelli L, Ferrucci R, Poletti B (2022) Diagnostic properties of the frontal assessment battery (FAB) in Huntington’s disease. Front Psychol 13:1031871
pubmed: 36533005 pmcid: 9748548 doi: 10.3389/fpsyg.2022.1031871
Spielberger CD, Gonzalez-Reigosa F, Martinez-Urrutia A, Natalicio LF, Natalicio DS (1971) The state-trait anxiety inventory. Interam J Psychol 5:145–158
Spinnler H, Tognoni G (1987) Standardizzazione e taratura italiana di una batteria di test neuropsicologici. Neurol Sci 6:S1–S120
Varalta V, Picelli A, Fonte C, Amato S, Melotti C, Zatezalo V, Smania N (2015) Relationship between cognitive performance and motor dysfunction in patients with Parkinson’s disease: a pilot cross-sectional study. BioMed Res Int 2015:365959
pubmed: 25918713 pmcid: 4396143 doi: 10.1155/2015/365959
Varanese S, Perfetti B, Ghilardi MF, Di Rocco A (2011) Apathy, but not depression, reflects inefficient cognitive strategies in Parkinson’s disease. PLoS ONE 6:e17846
pubmed: 21437255 pmcid: 3060914 doi: 10.1371/journal.pone.0017846
Vlagsma TT, Koerts J, Tucha O, Dijkstra HT, Duits AA, van Laar T, Spikman JM (2017) Objective versus subjective measures of executive functions: predictors of participation and quality of life in Parkinson disease? Arch Phys Med Rehabil 98:2181–2187
pubmed: 28427928 doi: 10.1016/j.apmr.2017.03.016
Wallace ER, Segerstrom SC, van Horne CG, Schmitt FA, Koehl LM (2022) Meta-analysis of cognition in Parkinson’s disease mild cognitive impairment and dementia progression. Neuropsychol Rev 32:149–160
pubmed: 33860906 doi: 10.1007/s11065-021-09502-7

Auteurs

Edoardo Nicolò Aiello (EN)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, 20149, Milan, MI, Italy.

Alfonsina D'Iorio (A)

Department of Psychology, University of Campania "Luigi Vanvitelli", Caserta, Italy.

Federica Solca (F)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, 20149, Milan, MI, Italy.

Silvia Torre (S)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, 20149, Milan, MI, Italy.

Ruggero Bonetti (R)

Neurology Residency Program, Università Degli Studi Di Milano, Milan, Italy.

Francesco Scheveger (F)

Neurology Residency Program, Università Degli Studi Di Milano, Milan, Italy.

Eleonora Colombo (E)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, 20149, Milan, MI, Italy.

Alessio Maranzano (A)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, 20149, Milan, MI, Italy.

Luca Maderna (L)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, 20149, Milan, MI, Italy.

Claudia Morelli (C)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, 20149, Milan, MI, Italy.

Alberto Doretti (A)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, 20149, Milan, MI, Italy.

Marianna Amboni (M)

Institute of Diagnosis and Health, IDC-Hermitage Capodimonte, Naples, Italy.
Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.

Carmine Vitale (C)

Institute of Diagnosis and Health, IDC-Hermitage Capodimonte, Naples, Italy.
Department of Motor Sciences and Wellness, University "Parthenope", Naples, Italy.

Federico Verde (F)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, 20149, Milan, MI, Italy.
Department of Pathophysiology and Transplantation, "Dino Ferrari Center", Università Degli Studi Di Milano, Milan, Italy.

Roberta Ferrucci (R)

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Sergio Barbieri (S)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Eleonora Zirone (E)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Alberto Priori (A)

ASST Santi Paolo e Carlo, San Paolo University Hospital, Milan, Italy.
Department of Health Sciences, "Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, University of Milan, Milan, Italy.

Gabriella Pravettoni (G)

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Applied Research Division for Cognitive and Psychological Science, IEO, European Institute of Oncology, IRCCS, Milan, Italy.

Gabriella Santangelo (G)

Department of Psychology, University of Campania "Luigi Vanvitelli", Caserta, Italy.

Vincenzo Silani (V)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, 20149, Milan, MI, Italy.
Department of Pathophysiology and Transplantation, "Dino Ferrari Center", Università Degli Studi Di Milano, Milan, Italy.

Nicola Ticozzi (N)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, 20149, Milan, MI, Italy.
Department of Pathophysiology and Transplantation, "Dino Ferrari Center", Università Degli Studi Di Milano, Milan, Italy.

Andrea Ciammola (A)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, 20149, Milan, MI, Italy.

Barbara Poletti (B)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, 20149, Milan, MI, Italy. b.poletti@auxologico.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH